Anthony T. Reder, MD
Anthony T. Reder, MD
Professor of Neurology
Professor of Neuroscience Institute
Specialties
- Neurology
Locations
- Chicago - Hyde Park
Schedule an Appointment
Schedule an Appointment- About
- Specialties & Areas of Expertise
- Locations & Patient Information
- Education & Research
- Accepted Insurance
- External Professional Relationships
Meet Dr. Reder
Anthony T. Reder, MD, is an expert on multiple sclerosis (MS) and an instrumental faculty member in the University of Chicago Medicine's large MS program.
Dr. Reder and several other colleagues and residents have developed new treatments for MS. The group has shown that misoprostol (Cytotec) abolishes trigeminal neuralgia in MS. The MS group has also helped develop and test most of the current therapies for MS, including Interferon-beta (Betaseron, Avonex, Rebif, Extavia), glatiramer (Copaxone), natalizumab (Tysabri) and fingolimod (Gilenya). The first FDA-approved therapy, IFN-beta (Betaseron), reduced exacerbations of MS, improved memory and reduced deaths 20 years later by nearly 50 percent. Several other trials of new MS therapies are currently in progress.
Dr. Reder directs the Neurology and Inflammatory Disease Infusion Center. Here, cutting-edge therapies are used to treat multiple sclerosis, lupus, rheumatoid arthritis, sarcoidosis and Crohn’s disease.
Dr. Reder has authored a large number of papers and abstracts, and often makes presentations at national neurology meetings. Subjects have included multiple sclerosis, EAE, tetanus, neuropsychiatry, sleep and fatal familial insomnia. His primary research interest is in the interaction between the central nervous system (CNS) and the immune system. He and his colleagues are studying the mechanism of action for interferon — the most widely used treatment for MS.
Dr. Reder recently found that there is a defect in the interferon signaling pathway in lymphocytes during attacks and in progressive forms of MS. This may be why patients with progressive MS do not respond clinically to interferon therapy. He was recently awarded a grant from the National MS Society to study the cause of the signaling problem and ways to correct it.
Specialties
Areas of Expertise
- Tetanus
- Neuroimmunology
- Demyelinating Disease
- MOG Antibody Disease
- Neurosarcoidosis
- Optic Neuritis
- Transverse Myelitis
- Multiple Sclerosis
Board Certifications
- Neurology
Practicing Since
- 1978
Languages Spoken
- English
Medical Education
- University of Michigan
Internship
- Hennepin County M. C
Residency
- University of Minnesota
Memberships & Medical Societies
- American Academy of Neurology
- American Association for the Advancement of Science
- American Association of Immunologists
- American Clinical Laboratory Association
- American Neurological Association
- Association of University Professors of Neurology
- Brain Research Institute
- International Society for Interferon and Cytokine Research
- International Society of Neuroimmunomodulation
- Society for Experimental Neuropathology
News & Research
Insurance
- Aetna Better Health *see insurance page
- Aetna HMO (specialists only)
- Aetna Medicare Advantage HMO & PPO
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS Medicare Advantage HMO & PPO
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Choice HMO (specialists only)
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
*Click Here to visit our insurance page and learn more.
Some of our physicians and health professionals collaborate with external pharmaceutical, medical device, or other medical related entities to develop new treatments and products to improve clinical outcomes for patients. In some instances, the physician has ownership interests in the external entity and/or is compensated for advising or speaking about the entity’s products or treatments. These payments may include compensation for consulting and speaking engagements, equity, and/or royalties for products invented by our physicians. To assure objectivity and integrity in patient care, UChicago Medicine requires all physicians and health professionals to report their relationships and financial interests with external entities on an annual basis. This information is used to review relationships and transactions that might give rise to potential financial conflicts of interest, and when considered to be significant a management plan to mitigate any biases is created.
If you are a patient at UChicago Medicine and would like more information about your physician’s external relationships, please talk with your physician. You may also visit the Centers for Medicare & Medicaid Services (CMS) Open Payments website at https://openpaymentsdata.cms.gov/ . CMS Open Payments is a national disclosure program that promotes a more transparent and accountable health care system. It houses a publicly accessible database of payments that reporting entities, including drug and medical device companies, make to covered recipients like physicians and hospitals.
Information in the CMS Open Payments database could potentially contain inaccurately reported and out of date payment information. All information is open to personal interpretation, if there are questions about the data, patients and their advocates should speak directly to their health care provider for a better understanding.